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Abstract: Radiotherapy is used to treat approximately 50% of all cancer patients, with 
varying success. Radiation therapy has become an integral part of modern treatment 
strategies for many types of cancer in recent decades, but is associated with a risk of  
long-term adverse effects. Of these side effects, cardiac complications are particularly 
relevant since they not only adversely affect quality of life but can also be potentially  
life-threatening. The dose of ionizing radiation that can be given to the tumor is determined 
by the sensitivity of the surrounding normal tissues. Strategies to improve radiotherapy 
therefore aim to increase the effect on the tumor or to decrease the effects on normal 
tissues, which must be achieved without sensitizing the normal tissues in the first approach 
and without protecting the tumor in the second approach. Hyperthermia is a potent 
sensitizer of cell killing by ionizing radiation (IR), which can be attributed to the fact that 
heat is a pleiotropic damaging agent, affecting multiple cell components to varying degrees 
by altering protein structures, thus influencing the DNA damage response. Hyperthermia 
induces heat shock protein 70 (Hsp70; HSPA1A) synthesis and enhances telomerase 
activity. HSPA1A expression is associated with radioresistance. Inactivation of HSPA1A 
and telomerase increases residual DNA DSBs post IR exposure, which correlates with 
increased cell killing, supporting the role of HSPA1A and telomerase in IR-induced DNA 
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damage repair. Thus, hyperthermia influences several molecular parameters involved in 
sensitizing tumor cells to radiation and can enhance the potential of targeted radiotherapy. 
Therapy-inducible vectors are useful for conditional expression of therapeutic genes in 
gene therapy, which is based on the control of gene expression by conventional treatment 
modalities. The understanding of the molecular response of cells and tissues to ionizing 
radiation has lead to a new appreciation of the exploitable genetic alterations in tumors and 
the development of treatments combining pharmacological interventions with ionizing 
radiation that more specifically target either tumor or normal tissue, leading to 
improvements in efficacy. 
Keywords: heat shock proteins; radiotherapy; hyperthermia; cancer; hypoxia 
 
1. Introduction 
Heat shock proteins (HSP) have key roles in cellular stress response and immune modulation. 
Active areas of interest in the study of HSP and malignancy include their role as prognostic factors, 
predictors of response to treatment, and their dual role in both tumor cell protection when expressed at 
high levels within tumors and conversely tumor cell destruction through antigen presentation and 
processing of tumor-derived HSP-peptide complexes. A growing body of evidence supports the 
importance of HSP in human cancers in both the intracellular and extracellular environments. 
Intracellularly, HSP protect cells from proteotoxic stress by a variety of “holding and folding” 
pathways that prevent the formation of denatured proteins and the progression of lethal aggregation 
cascades by both necrotic and apoptotic pathways [1,2]. HSP also have a central role in modulation of 
the immune system, and Hsp72 (HSPA1A/B) can act as an immunological adjuvant [3,4]. Intracellular 
HSPA1A/B binds processed peptides derived from antigens and shuttles them to the cellular 
transporter associated with antigen processing (TAP). HSPA1A/B also appears to have additional 
effects on cytotoxic T-lymphocytes (CTL) that do not require the binding of tumor associated antigens 
to the HSP. Purified HSPA1A/B induces the activation of CD8
+ CTL and the secretion of tumor 
necrosis factor-alpha (TNF-α) and IFN-γ in the absence of peptide loading [5]. The impact of HSP 
outside the cell has been further revealed in recent years. HSPA1A/B, added exogenously to cells, 
stimulates the production of pro-inflammatory cytokines TNF-α, interleukin-1 beta (IL-1β) and IL-6 
by antigen-presenting cells (APC) [6-8]. This process is referred to as the chaperokine activity of 
HSPA1A/B. HSPA1A/B appear to play a role in other aspects of non-specific immune responses: 
HSPA1A/B is found on the cell surface of some tumor cells and is a target of lymphoid activated killer 
(LAK) cells [9,10]. The majority of studies exploring the role of HSPA1A/B in cellular and immune 
regulation have been at the pre-clinical level. To date, studies of HSPA1A/B in human malignancies 
have largely focused on defining the expression of HSPA1A/B in extracted malignant tissue typically 
obtained at the time of diagnosis [11,12]. Relatively little is known about circulating serum levels of 
HSPA1A/B [13] and to date the impact of common cancer treatments on circulating HSPA1A/B has 
been undefined. As characterization of HSP profiles in clinically relevant settings may lead to 
development of specific new treatment strategies for cancer eradication, the present study was Cancers 2011, 3                               
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designed to assess the extracellular expression of HSPA1A/B and its potential effect on immune 
system response in patients undergoing treatment for prostate cancer. Subsequently, in vivo and  
in vitro studies were performed to further validate and characterize the clinical findings including the 
potential for tumor specific immune response and mechanisms for HSP release from intact   
irradiated tumors. 
2. Cellular Mechanisms of Heat Shock Response 
During evolution, cellular systems have developed mechanisms to adapt to thermal stress and the 
major target proteins induced by thermal stress are the HSP, which function as chaperones. They are 
involved in prevention of misaggregation of denatured proteins after stress. HSP also play a role in 
proper folding of nascent proteins into their required functional conformation. These proteins further 
regulate the protein turnover and also the cellular redox-state [14]. The best-known HSP are members 
of the HSP40 (DNAJB1), HSP60 (HSPD1), HSPA1A and HSP90 (HSP90AB1) families. They are 
highly conserved across prokaryotes and eukaryotes, which points to their importance in cellular 
protection mechanisms [15]. The mechanisms mediating heat shock response were shown to be not 
strictly specific for heat only. Interestingly, they are often also cross-protective for other stress factors. 
In fact, this variation in cellular responses is decisive for using hyperthermia to force cells into 
apoptotic/necrotic pathways for therapeutic purposes as desired in clinical settings. 
Heat-induced HSP expression is mediated by specific promoter sequences, the heat shock elements 
(HSE). The actual heat-response of these promoters is mediated by the activity of heat-shock factors 
(HSF), which bind to these HSE sequences and mediate expression of their specific target genes, such 
as HSP. Three HSF (HSF-1, 2 and 4) have been identified in mammalian cells, which possess 
additional isoforms for functional variation [16]. Among those, HSF-1 is the key player in   
heat-mediated gene expression regulation, whereas HSF-2 and HSF-4 activity is not directly linked to 
heat-responsive regulation of gene expression. In non-heated cells, HSF-1 is localized as a monomer in 
the cytoplasm and is bound to HSP (e.g. HSPA1A, HSPAB1). During heat activation, HSF-1 is 
released from HSP and enters the nucleus. In this state of activation, HSF-1 is constitutively   
hypo-phosphorylated as a monomer. After entering the nucleus, HSF-1 monomers trimerize and are 
then inducibly hyper-phosphorylated [17]. The phosphorylation status of trimeric HSF-1 is of essential 
importance for the DNA-binding activity and decisive for the ability to induce transcription [18]. In 
addition, presence of multiple HSE within a promoter is enhancing heat-inducibility of gene 
transcription exploited for the construction of heat responsive gene expression vectors in gene therapy. 
The strong and efficient activation of HSF-1 mediated transcription activation is one major factor that 
made this conditional system attractive for gene therapeutic uses.  
Heat shock induces inhibition of DNA-synthesis and transcription, mRNA-processing and 
translation, and blocks the progression through cell cycle. The denaturation and misaggregation of 
proteins is increased leading to enhanced proteasomal and lysosomal degradation [19]. Heat shock 
leads also to the disruption of cytoskeletal components and changes in membrane permeability with 
changes in gene expression for increase of cellular thermotolerance [20].  
Over-expression of HSPA1As and HSPAB1s in many tumors [21] correlates with the cellular 
proliferation and survival of oral [22], colorectal [23], and breast cancers [24]. Over-expression of Cancers 2011, 3                               
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HSPA1A or the less highly conserved HSP27 (HSPB1) protein increases cellular resistance to 
hyperthermia and other forms of stress by both maintaining normal cellular functions and blocking 
apoptotic cell death [25]. HSP110 (HSPA4) expression has also been shown to result in a small 
increase in thermoresistance [26]. Low-level synthesis of HSPA1A can occur in cultured human cells 
and is also detected in specific tissues from both mice and humans but appears to be upregulated in 
many cancer cell lines. Regulation of basal level synthesis in human cells is mediated through serum 
response elements present in the HSPA1A promoter [27], whereas the substantial increase in cellular 
levels of HSPA1A and other HSP following heat treatment is mediated by HSF-1.  
HSPA1A is a highly conserved protein in all organisms, and is composed of three domains, namely 
N-terminal ATPase domain, substrate-binding domain, and C-terminal lid [28]. It assists in the folding 
of a large variety of proteins via the association of its substrate binding domain with hydrophobic 
peptide segment within its substrate proteins in an N-terminal ATPase domain-dependent manner. 
Furthermore, HSPA1A function is highly regulated by cochaperones through its interactions with the 
C-terminal lid. HSF mediates the heat shock response by binding to the HSE at the promoter of the 
HSP70  gene, and subsequently initiating transcription through formation of active transcription 
complex assembly [29].  
3. Heat-Responsive Gene Therapy Systems 
Hyperthermia has gained acceptance for cancer therapy of breast carcinoma, colorectal carcinoma, 
malignant melanoma, head and neck cancer, cervical cancer, esophageal cancer, soft tissue sarcoma, or 
glioblastoma [30]. A considerable additive or synergistic improvement of therapeutic efficacy can be 
achieved by combination of chemotherapy, radiation or hyperthermia with gene therapy employed for 
the regulated expression of cytokine or suicide genes. Hyperthermia ranging from 39 °C up to 48 °C 
induces transgene expression, representing a promising strategy could be particularly beneficial, which 
augment the effects of hyperthermia at both cellular and systemic levels. To achieve this, different 
promoters have been used for construction of viral and nonviral vectors and were tested in numerous 
gene therapy studies for heat-inducible gene expression [31].  
The direct approach for combining hyperthermia with gene therapy is the use of expression vector 
systems, which employ heat responsive promoters for transgene expression control. The human 
HSP70B promoter was most frequently used due to low-leakiness and the high-level heat-induced 
transgene expression, which can be achieved in vitro and in vivo [32]. For melanoma treatment,   
heat-induced IL-12 expression with detectable elevated systemic release of the cytokine in association 
with anti-tumoral efficacy under HSP70B promoter was used [33]. The anti-tumoral effects under 
HSP70B promoter were further enhanced if heat-responsive IL-12 expression was combined with 
radiation. The heat shock protein 70 family is a family of multifunctional repair/removal agents for 
denatured and damaged proteins that can enhance cell survival following injury caused by many 
different agents including heat, radiation, and chemotherapeutic agents. Basal level cellular expression 
of inducible HSPB1 is upregulated in many cancer cells and confers a high level of resistance to 
radiation and chemotherapeutic agents in the absence of heat.  
The most prominent developments in this regard are the uses of focused ultrasound (FUS) and of 
magnetic nanoparticles for temporal and spatial control of heat-responsive gene therapy. Technical Cancers 2011, 3                               
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improvements of FUS allow the non-invasive and strictly controlled heating of defined tumor volumes 
[34]. The combination of FUS with magnetic resonance imaging (MRI) allows the real-time 
monitoring and feedback control of the applied temperature [35].  
In an alternative approach, magnetic nanoparticles are used to mediate hyperthermia in the 
transduced tissue area. For this, either magnetic cationic liposomes containing the magnetic particles 
and DNA or DNA-loaded magnetic nanoparticles were used. These nanoparticles mediate the heating 
of the targeted tissue, if alternating magnetic fields are applied. The application of AMF to these 
tumors caused effective heating of the tissue in association with the induction of the GADD153 
promoter-driven TNF-α expression [36]. In a comparable approach, magnetic Mn–Zn ferrite 
nanoparticles were employed, which had improved capacity for DNA-loading due to their surface 
modification with cationic polyethylenimide. Intratumoral injection of these nanoparticles and 
application of AMF led to hyperthermia of 39.5 °C or 42.8 °C in the tumors, which causes efficient 
heat-induced HSP70B promoter-driven Lac-Z expression. The attractiveness of using nanoparticles 
lies in the combination of a heat generating system at the cellular level and in its potential as an 
efficient gene delivery technology.  
4. Heat Shock and DNA Damage Response 
Heat is a pleiotropic damaging physical agent that affects several cellular components to varying 
degrees; altering protein metabolism, thus affecting the assembly and stability of critical 
macromolecular complexes. DNA damage inflicted by ionizing radiation triggers the DNA damage 
response, molecular events that mostly involve the post-translational modification of proteins that 
activate intracellular signaling pathways [37]. Several cell cycle checkpoints are in place that, on 
damage such as that inflicted by ionizing radiation, allow the repair, and prevent the propagation, of 
the damaged DNA. Cells may be halted in their transition from G1 phase to S phase of the cell cycle, 
intra-S phase and at the G2/M boundary [38]. A defective DNA damage response, in particular a 
failure to halt the cell cycle, is a feature that is common to many cancers [37]. Some cancer-prone 
human syndromes arise from defects in specific DNA damage response and DNA repair genes, such as 
ataxia telangiectasia mutated (ATM), nibrin (also known as NBS1), BRCA1 and BRCA2 [39]. The 
absence of functional BRCA1 or BRCA2 impairs the ability to repair DSB by HR with additional loss 
of PARP1 activity, which drives BER and SSBR, then increases the formation of lesions (unrepaired 
endogenously occurring SSBs) that are repaired by BRCA1-and BRCA2-dependent HR. As a result, 
cells die from endogenous metabolically induced DNA damage [40]. Oncogene-driven DNA 
replication stress has been implicated as a cause of constitutive activation of the DNA damage 
response and tumor progression [39]. Defects in both DNA repair and checkpoint responses in tumor 
cells affect the response to ionizing radiation and can be exploited for targeted radiosensitization 
strategies. 
Ionizing radiation induces a variety of DNA lesions, including oxidized base damage, abasic sites, 
single-strand breaks and double-strand breaks. The activity of the DNA repair processes that deal with 
such damage has long been known to determine the response to ionizing radiation [41]. Deficiencies in 
pathways that repair double-strand breaks, thought to be the most lethal lesion induced by ionizing 
radiation, such as non-homologous end joining and homologous recombination, are particularly Cancers 2011, 3                               
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detrimental to the cells [42]. However, it has become increasingly evident that other repair processes 
are also needed to ensure genome integrity and survival after ionizing radiation like base excision 
repair [43], which repairs base damage and single-strand breaks [44] that can be converted to double-
strand breaks when encountering a replication fork. Secondary double-strand breaks can also result 
from repair attempts at complex clustered damage sites that are characteristic of ionizing radiation 
[45]. These considerations have led to the development of a range of novel compounds that influence 
DNA repair after chemotherapy and radiotherapy, with the ultimate goal of sensitizing tumor cells to 
the treatment. Inhibitors of important molecules in double-strand breaks repair, such as ATM or   
DNA-dependent protein kinase (DNA-PK), have been shown to sensitize cancer cells and xenografted 
tumors to radiotherapy. The preclinical evaluation of PARP inhibitors has shown that they can increase 
tumor responses to ionizing radiation in xenograft models. Several PARP inhibitors have already 
entered clinical trials, and assessments of the combination of PARP inhibitors with radiotherapy are 
underway [46]. The common overexpression of AP endonuclease (also known as APEX1), which is 
crucial in base excision repair, and its role in determining radiotherapy and chemotherapy response 
was the basis of the development of APE inhibitors [47].  
Besides DNA repair, cell cycle checkpoints constitute the other important component of the DNA 
damage response. DNA damage-induced G1/S cell cycle checkpoint activation is almost universally 
absent in cancer cells, and this absence is frequently caused by mutations in p53 or p53-regulatory 
processes [48]. However, p53-deficient tumor cells must rely on the S or G2 checkpoints more heavily 
than normal cells for their survival, which could be exploited therapeutically, because premature 
mitotic entry would expose the tumor cells to additional damage [49]. The induction of DNA damage 
by ionizing radiation in normal cells will halt their progression through the cell cycle, preventing 
further accumulation of damage and its serious consequences.  
The ataxia-telangiectasia mutated gene product (ATM) is a protein kinase primarily activated in 
response to DNA DSBs caused by IR or radiomimetic drugs. Unstressed cells contain inactive ATM in 
a dimer or higher-order multimer form. Heat is known to induce chromatin alterations [50]. 
Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand 
breaks and HSPA1A status [51]. Heat treatment before radiation exposure also had no significant 
effect on chromosomal DNA strand break induction by IR [51]. Heat shock caused a change in the 
nucleoid halo diameter, but no inhibition of DNA rewinding [51]. In contrast, IR exposure results in a 
significant inhibition of DNA loop rewinding. Moreover, the nucleoid diameter (which reflects the 
length of the DNA loops at maximum relaxation) was reduced after heat shock, whereas IR exposure 
resulted in an increase in nucleoid diameter. Furthermore, Hunt and coworkers did examine whether 
heat shock induces G2-type chromosomal aberrations or inhibited repair of DNA strand breaks or 
effects both processes [51]. Hunt and coworkers reported that the number of chromosome aberrations 
detected after irradiation with 0.15 Gy was statistically significant as compared with unirradiated cells 
[51]. Irradiated cells had detectable levels of chromosomal aberrations after a 0.15 Gy exposure, and 
no aberrations have been reported in cells that were treated with heat alone [51].  
Ionizing radiation also activates the NF-κB pathway through the activation of IκB kinase-α (IKKα; 
also known as CHUK) as a protective response to damage, and inhibition of this kinase can lead to 
increased radiosensitvity. Inhibition of the MAPK pathway can also lead to increased radiosensitivity 
through reduced double-strand breaks repair by both homologous and non-homologous pathways, Cancers 2011, 3                               
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possibly through the regulation of ATM. The mechanisms by which many of these signal transduction 
pathways influence radiosensitivity are not completely clear. AKT, MAPK and NF-κB signaling can 
all inhibit the apoptotic response after DNA damage [52]. The link between the AKT, MAPK and 
TGF-β pathways and DNA repair have been found, particularly with DSB repair by NHEJ or HR [53]. 
Because inhibition of these repair pathways causes marked increases in radiosensitivity, this is perhaps 
the most plausible mechanism that links the signal transduction discussed above to cell kill after 
irradiation. 
Two aspects of the tumor microenvironment have been widely investigated with respect to 
improving radiotherapy, namely hypoxia (lack of oxygen) and vasculature development. Because 
hypoxia seldom occurs in normal tissues, it is an attractive tumor-specific target for improving the 
response to ionizing radiation [54]. Oxygen concentrations of less than 0.02% (0.15 mm Hg) render 
cells more resistant to killing by ionizing radiation by a factor of 2–3 (ratio of doses under hypoxia 
versus normoxia to produce equal cell kill) mainly as a result of the radiochemical fixation of DNA 
damage by molecular oxygen. Hypoxia leads to the activation of the hypoxia-inducible factor (HIF) 
and unfolded protein response (UPR) pathways, which both determine survival under this stress [55]. 
High expression of hypoxia-inducible genes is often associated with poor prognosis [56]. Several 
drugs underwent clinical testing, although the only one to show efficacy in Phase III trials and to 
remain in routine clinical use is the 5-nitroimadazole nimorazole [57]. The efficacy of such schedules 
is more at risk from radioresistant hypoxic subpopulations than conventional schedules in which there 
is more opportunity for the reoxygenation of hypoxic cells during treatment. Recent more extreme 
hypofractionization schedules are thus likely to benefit most from the use of hypoxic cell 
radiosensitizers [58]. 
The compounds have been developed that kill hypoxic cells with far greater efficiency than 
normoxic cells, which is an alternative to radiosensitizing hypoxic cells and modeling studies indicate 
that it is the more effective strategy to combine with radiotherapy [59]. New, less toxic drugs are 
needed, and some tirapazamine analogues are looking promising [60]. Model compounds that reduce 
hypoxic tolerance have shown efficacy in preclinical models, demonstrating increased ionizing 
radiation responses resulting from reduced hypoxic fractions [61]. Vasculogenesis also depends on 
hypoxia, which is more extensive in recurrent tumors, leading to the upregulation of cytokines that in 
turn recruit and activate the BMDCs that are necessary for vascular formation [62]. In preclinical 
models, inhibiting vasculogenesis by various interventions, both genetic and pharmacological, 
dramatically increased tumor responses after radiotherapy and was more effective than inhibiting 
angiogenesis [63]. 
5. Hyperthermia: Mechanisms and Therapeutic Use 
The success of heat-responsive gene therapy greatly depends on whether hyperthermia can be 
applied efficiently and in a controlled manner to the desired tissue. It is an essential requirement that 
the applied heat has the temperature level, timely defined duration and spatial control to activate 
efficiently the heat-responsive vector. To achieve this, already clinically used hyperthermia systems 
could be employed for local, regional or whole body application of hyperthermia. In analogy to these 
clinically established technologies, similar and also novel approaches are used for controlled Cancers 2011, 3                               
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hyperthermic activation of heat-responsive vectors [30]. The first clinical applications of hyperthermia 
(between 39.5 °C and 43 °C) were performed for treatment of superficious tumor lesions, showing 
some efficacy [64]. Local hyperthermia has been established for treatment of superficious lesions 
using specific antennas or applicators to emit micro- or radiowaves for heat generation in the tumor 
lesion reaching depths of only a few centimeters. Applicators are implanted within the tumor to treat 
relatively small lesions (b5 cm) for the interstitial and endocavitary hyperthermia. In contrast to these 
locally restricted hyperthermia treatments, the whole-body hyperthermia are applied for treatment of 
cancers with distant metastases. In this treatment a maximum temperature of 42 °C can be maintained 
for 1 h to prevent severe adverse side effects. Improvement in clinical outcome has been shown for 
tumors of the head and neck, breast, brain, bladder, cervix, rectum, esophagus and for melanoma. In 
these trials, combination of hyperthermia with radio- or chemotherapy generated best results, due to 
the sensitizing activity of the applied hyperthermia [65]. 
5.1. Hyperthermia and Hypoxia 
Invasion into adjacent tissues and metastasis to distant sites are major features of cancer cells and 
the cause of 90% of human cancer death [66]. Acquisition of invasive and angiogenic potential is thus 
critical for metastasis where hypoxia-inducible factor-1 (HIF-1) pathway plays a pivotal role [67-69]. 
Hypoxia exists in proliferative tumors and the extent of tumor hypoxia correlates with tumor 
progression and metastasis [70]. Under hypoxia, HIF-1α protein is stabilized, dimerized with HIF-1β, 
and thus can bind to the hypoxia response element to transactivate a battery of genes involved in the 
promotion of angiogenesis and glucose metabolism to adapt to a stressful environment [71]. The 
induction of these genes not only gives tumors a survival advantage, but also promotes invasion and 
angiogenesis [69,71]. Recent studies have suggested that RTK signaling transcriptionally induces   
HIF-1α [72,73] while hypoxia enhances RTK signaling via HIF-1-mediated up-regulation of RTKs 
[74-76] and the reciprocal relationship between the two distinct oncogenic pathways promotes cancer 
invasion and angiogenesis [74-76]. HIF-1 transactivates a variety of genes including RTKs [69,74-76], 
urokinase-type plasminogen activator (uPA) [77], uPA receptor [71,78], MMP2 [71] and VEGF [69], 
eventually promoting cancer progression. VEGF, the most potent angiogenic factor, stimulates 
angiogenesis by binding to and activating its cell surface receptor, promoting endothelial cell 
proliferation and migration. The stability of VEGF receptors depend on HSP90AB1 function and thus 
HSP90AB1 inhibitors destabilize VEGF receptors [79,80]. Therefore, HSP90AB1 inhibitors 
efficiently block the proliferation and differentiation of endothelial cells, consequently inhibiting the 
neovascularization of proliferating tumors. 
6. Radiotherapy 
Approximately 50% of all cancer patients will receive radiotherapy of some form (such as external 
beam or internal irradiation given as brachytherapy), either alone or in combination with other 
treatment modalities such as surgery or chemotherapy [81]. For some cancers survival rates after 
radiotherapy are high (like early stage larynx cancer and non-small-cell lung cancer), whereas for 
many other cancer sites they are not (e.g., glioblastomas, sarcomas and advanced non-small-cell lung 
cancer). Accurate delivery of the ionizing radiation dose has greatly improved over the past 2–3 Cancers 2011, 3                               
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decades, allowing more precise deposition of dose in the tumor while progressively reducing any 
unwanted dose to surrounding normal tissues [82]. Despite such technical improvements, and despite 
the fact that radiotherapy is one of the most effective forms of cancer treatment, many patients still 
suffer from locally recurrent disease after radiotherapy. Clinical factors can explain some of the 
failures, such as a large tumor and/or advanced tumor stage, which translate into more tumor cells to 
kill with the same ionizing radiation dose, thus reducing the local control probability. However, many 
tumors with apparently similar sizes, stages, grades and delivered doses, some will recur and some will 
not (control rates for many such ‘homogeneous’ populations are not 0% or 100%).  
6.1. Hyperthermia Enhances Radiation-Induced Cell Killing 
Hyperthermia is used to treat external tumors such as sarcoma [83], cervix [84] or with surgically 
accessible tumors such as prostate [85] and liver [86]. Agarwal and coworkers used multiple 
approaches to determine the effect of telomerase inactivation on heat- and IR-induced cell killing 
because telomerase activation has been linked with extension of cell life span. Hyperthermia is a 
potent radiosensitizer that has been under clinical investigation as a means to improve the response to 
ionizing radiation (IR)–based cancer treatments, and acts to improve the local tumor control. Recently, 
the circulating levels of HSPA1A/B in serum in cancer patients are of interest in both defining 
prognostic significance and identifying a potential target for new therapeutic strategies, such as 
radiotherapy [87]. Cornford et al. assessed the expression of intracellular HSP in tissue obtained from 
patients with early prostate cancer either at the time of prostatectomy or as an incidental finding at the 
time of transurethral resection of the prostate (TURP) as well as from patients with advanced disease 
obtained at the time of TURP [88] and compared with those of control patients with tissue obtained at 
the time of cystectomy. Immunohistochemical analysis of HSPA1A/B expression revealed similar 
expression of HSPB1 in early prostate cancers compared with non-neoplastic controls, but diminished 
expression was noted in morphologically advanced cancers. Plasma HSPA1A/B levels were measured 
in 125 patients with localized/untreated or hormone refractory prostate cancer and compared with 
levels for 45 healthy male donor controls of similar age. Plasma HSPA1A/B levels in patients with 
localized untreated disease were significantly higher than those in the control group. While a primary 
cutoff point for plasma HSPA1A/B was defined that significantly distinguished the localized untreated 
patients from the control group, plasma HSPA1A/B was not more effective than PSA as a predictor for 
diagnosis or stratification of patients into established risk groups [13]. Our group further assessed the 
impact of common treatments for prostate cancer on serum HSPA1A/B levels and to characterize its 
mechanism of release and biological significance using Mouse orthotopic xenograft of human prostate 
cancer. There was no increase with AST, but a significant increase in circulating serum HSPA1A/B 
was noted in response to radiotherapy. Also, there was a significant increase in cells phenotypically 
characterized at CD8
+ cytotoxic T lymphocytes and CD56
+ natural killer (NK) cells and a concomitant 
increase in the pro-inflammatory cytokines IL-6 and TNF-α. Zitvogel et al., showed that exosomes 
produced by mouse DC pulsed with tumor peptides induce the rejection of established tumors in an 
antigen specific, T cell-dependent fashion in which the anti-tumor effects were associated with   
long-term survival [89]. Indeed, this property of exosomes is currently being assessed for its potential 
as a cancer vaccine in phase I clinical trials [90]. Our group hypothesized that radiotherapy stimulates Cancers 2011, 3                               
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the passive and active release of HSPA1A/B from tumors. Passive release is achieved by the direct 
radiotherapy-induced necrosis of tumors. This liberates heat shock protein peptide complexes   
(HSP-PC) which bind to and stimulate APC to produce pro-inflammatory cytokines, chemokines and 
reactive oxygen species, increase the expression of costimulatory molecules and augments the 
maturation of dendritic cells, a process known as the chaperokine activity of HSPA1A/B found in the 
extracellular milieu [91-93]. Recently, it was demonstrated that HSPA1A/B can also be induced by an 
active process [94]. Consistent with our findings in prostate cancer patients, radiation exposure 
resulted in a significant increase in serum HSPA1A/B concentrations in both human xenografts and 
syngeneic tumor-bearing mice. The dose-dependent nature of HSPA1A/B levels in response to 
radiation directly results in maximum release of HSPA1A/B into the serum by 24 hours post-exposure 
and returned to baseline values by 96 hours in both human xenografts and syngeneic tumor-bearing 
mice. Also, we demonstrated that HSPA1A/B was released into circulation in response to irradiation in 
a similar fashion as HSPA1A/B, albeit to lesser levels in DU-145 human xenograft as compared to 
PC-3 human xenograft. Interestingly, the kinetics of HSPA1A/B release induced by gamma irradiation 
peaked at 48 hours post exposure, whereas HSPA1A/B peaked at 24 hours in both PC-3 and DU-145 
prostate cancer cells, which is indicative of a difference in the mechanism by which HSPA1A/B is 
transported within the cell and subsequently released into the extracellular milieu, as compared with 
HSPA1A/B.  
Ionizing radiation as applied in the radiotherapy clinic induces a complex response in cells. Some 
processes aim to repair damage, whereas others counteract propagation of the damage or induce cell 
death. Tumor-targeted radiosensitization that partly depends on impaired DNA repair processes that 
result from mutated DNA repair genes within tumors. Hypoxia down regulates the expression of repair 
proteins and affects HR [95]. The repair of DNA damage is crucial to genomic integrity, and 
deficiencies in repair are known to have a large influence on cellular survival after ionizing radiation. 
More recently, it has also been shown that aberrantly activated signal transduction pathways in cancer 
cells can influence cellular radiosensitivity. Finally, the damage caused by ionizing radiation is 
markedly affected by oxygen levels, and irradiation under hypoxic conditions, as occurs in most 
tumors, reduces cell kill.  
6.2. Radiation-Induced Damage 
Data on cardiac complications after radiotherapy for the loco-regional management of breast cancer 
are distinguished from many other data sets as many breast cancer patients have been treated in clinical 
trials enabling systematic investigations over many decades. The results of these analyses prove 
radiation-induced cardiac complications on the one hand, while on the other they reflect the 
improvements in radiotherapy planning and delivery during these years, which greatly contributed to 
avoidance of the heart and diminished the risk of side effects. Cardiac toxicity has been implicated as 
the primary cause of excess non-breast cancer mortality in early breast cancer radiotherapy studies. An 
estimate of the aggregate incidence of radiation-induced cardiac disease is between 10% and 30% by 
5–10 years after treatment. Up to 88% of patients have asymptomatic abnormalities. Until recently, the 
cardiovascular system has been considered as relatively radio-resistant. In radiotherapy, the currently 
recommended tolerance dose for the heart is 40 Gy in fractions of 5 x 2 Gy/week if the whole organ is Cancers 2011, 3                               
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irradiated (risk of pericarditis). If only parts of the heart are exposed, even higher tolerance doses  
are accepted, i.e., 45 Gy if a volume of 66% is affected and up to 60 Gy if a volume of 33% is 
irradiated [96]. Epidemiological findings even indicate that the heart might be one of the most critical  
dose-limiting organs in radiotherapy.  
Different groups of people have been exposed to low doses (<1 Gy) of radiation to the heart. 
Among these are nuclear industry workers [97] and patients receiving radiation for diagnostic 
purposes. Radiologists and other medical workers received relevant occupational doses of radiation in 
the first half of the 20th century, when radiation protection measures were given only scant 
consideration [98]. Awareness of the potential risk of late cardiovascular disease after exposure to low 
radiation doses was initiated by a recent analysis of mortality from cancer and nonmalignant diseases 
among atomic bomb survivors in Japan. These individuals received one whole-body exposure.   
High-dose radiation to the heart can damage all cardiac structures and peripheral vessels with variable 
onset. All these forms of damage differ with regard to their probability after radiation exposure, 
latency and clinical features and lead to distinct histopathological changes. Often, several cardiac 
structures are affected, such that combinations of conditions occur. Pericardial damage leading to  
fibrous thickening and fluid production is one of the most frequently described forms of damage. 
Pericarditis may occur with a latency of months or years if large volumes of the heart receive doses of 
more than 40 Gy. Most cases start as asymptomatic exudative pericarditis, which progresses in   
approximately 20% of patients who develop either constrictive pericarditis or cardiac tamponade with 
hemodynamic compromise. The incidence of pericarditis has decreased with improvements in the  
conformality of dose distribution. Damage to the myocardium causes myocarditis, which can lead to 
progressive diastolic dysfunction and restrictive hemodynamics (≥1 year after irradiation), ending in 
congestive heart failure. These clinical complications correlate with diffuse interstitial fibrosis and  
microcirculatory damage leading to capillary obstruction or extensive fibrosis. Symptomatic 
cardiomyopathy during or shortly after radiotherapy is only seen in combination with anthracycline 
chemotherapy. 
Damage to the vascular system can trigger arteritis with premature coronary artery disease and 
accelerated atherosclerosis, which leads to ostial and proximal stenosis of the coronary arteries, which 
is characteristic of radiation-induced coronary artery disease. Vascular lesions correspond to intima 
hyperplasia and lumen wall collagen deposition, and finally atherosclerosis can lead to (fatal) cardiac 
infarction. Damage to vessels can also pertain to pulmonary vessels leading to pulmonary 
hypertension. The risk for coronary heart disease seems to be increased by doses as low as 1–2 Gy to 
the whole organ, especially if delivered as whole-body exposure. Seldom sequelae are endocardial and 
valvular damage progresses over time with stenosis and regurgitation. Pathological correlates are 
valvular cusp and/or leaflet fibrosis. The development of valve disease is similar to the general 
population regarding hemodynamics, natural history, and progression. Autonomic dysfunction leads to 
supraventricular tachycardia or heart rate variability. The frequency of conduction abnormalities in  
asymptomatic cancer survivors attributable to radiation only is unknown since causality is difficult to 
investigate. 
Systematic morphometric studies in rats show that capillary volume and length density begin to 
decline approxi–mately 20 days after heart irradiation, and that the decline continues in a dose-de-
pendent manner. In rats, myocardial cell death, reduced myocardial density, and degeneration occur Cancers 2011, 3                               
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10–20 weeks after irradiation, coincident with early signs of decreased cardiac function. The relevance 
of these mechanisms is supported by clinical studies showing regional perfusion defects in breast 
cancer patients between 6 months and 5 years after irradiation, which is related to the volume of the 
left ventricle included in the irradiated field. In the case of capillary rarefaction, there is a loss of the 
endothelial cell marker enzyme, alkaline phosphatase increases with time, which is involved in 
regulating endothelial cell proliferation and microvascular blood flow by dephosphorylating 
extracellular nucleoside phosphates. Ultrastructural studies showed that the enzyme loss was not 
caused by a loss of endothelial cells but associated with signs of endothelial cell activation, such as 
swelling, lymphocyte adhesion, and extravasation. In larger vessels, radiation induces oxidative stress 
in the endothelium, leading to accelerated development of intimal thickening and the formation of 
vulnerable inflammatory atherosclerotic plaques leading to monocyte adhesion and transmigration into 
the subendothelial space. 
Chronic inflammation is a major pathophysiological factor contributing to the development of 
atherosclerosis [99]. In atomic bomb survivors, C-reactive protein, interleukin 6, tumor necrosis factor 
α, and interferon-γ increased with radiation dose, which results suggest significantly increased 
inflammatory activity after whole-body exposure, which might partially explain the increased   
incidence of ischemic heart disease in atomic bomb survivors despite the low dose to the heart.   
Anti-inflammatory and anti-coagulant therapies were less effective at inhibiting radiation-induced 
atherosclerosis than age-related atherosclerosis, suggesting a more complex mechanism for lesion 
development after irradiation. One approach is to inject mesenchymal stem cells overexpressing 
hepatocyte growth factor (HGF) or a replication-deficient adenovirus carrying the HGF gene to 
stimulate the regeneration of cardiomyocytes. A further treatment approach might be statins, which are 
used to treat spontaneous heart disease by reducing the production of cholesterol. In this indication, 
statins reduce inflammation, slow the formation of new atherosclerotic plaques, occasionally reduce 
the size of existing plaques, stabilize plaques and make them less prone to rupturing and forming clots.  
6.3. Differential Effects of Lethal and Non-lethal Temperatures 
Hyperthermia can be used by itself and results in impressive shrinkage and even complete 
eradication (10-15%) of tumors, but usually do not last and the tumors regrow. Combined 
hyperthermia and radiation has been reported to yield higher complete and durable responses than 
radiation alone in superficial tumors. Hyperthermia is one way to overcome the radio resistance of 
tumor cells. It is possible to combine hyperthermia safely with further low-dose radiation in the 
situation where a radical dose has already been delivered. In addition, there seems to be evidence that 
whole body hyperthermia provides a measure of protection against radiation-induced 
thrombocytopenia. Hyperthermia improves the therapeutic index of TBI (total body irradiation), not 
only by increased neoplastic cell kill, but also by inhibiting the expression of radiation-induced 
damage to the normal cell population. Some agents not cytotoxic at normal temperature show cell 
killing abilities at higher temperatures: alcohols, amphotericin B, cysteine, and cysteamine. The new 
agents interferon, TNF and lonidamine and some hypoxic cell sensitizers are all potentates by heat. 
Hyperthermia can augment the cytotoxicity without increasing myelosuppression, and reverse drug 
resistance to chemotherapeutic agents. It has been shown in several studies that the use of Cancers 2011, 3                               
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hyperthermia can enhance the delivery of monoclonal antibodies to tumors with resultant improvement 
in anti-tumor effects. The spread into tissues of liposome-carried chemo drugs increases considerably 
compared to that under normal temperature. Hyperthermia is also an immune system enhancer, and 
very effective in providing pain relief, controlling bleeding, and useful in other conditions such as 
prostatic hypertrophy and psoriasis. 
Hyperthermia side effects for the external methods include pain, unpleasant sensations and burns in 
a small percentage of patients. In the case of the internal pyrogens, which are sometimes bacterial 
toxins, the situation is more complicated as bacterial toxins can induce serious, even fatal reactions in 
humans, depending on dosage. Ultrasound hyperthermia in areas where the tumor is over a bone will 
cause bone pain. Whole body hyperthermia can result in neuropathies. Extracorporeal systemic 
hyperthermia, where the blood is routed from the body as in dialysis has two advantage: higher 
possible temperatures and more homogeneous heating. The side effects, however, have been 
considerable with frequent persistent peripheral neuropathies, abnormal (and sometimes lethal) blood 
coagulation, some damage to liver and kidneys, and brain hemorrhaging and seizures. Hyperthermia 
should be administered to patients who are awake and can report any problems as they experience 
them. The clinical use of moderate hyperthermia in combination with ionizing radiation is thought to 
benefit from the complementary cell-cycle sensitivity of these two modalities because radioresistant  
S-phase cells are extremely heat-sensitive [100]. Specifically, increased cell-cycle delays in mid to late 
S/G2 phases were found to be associated with increased G2/M checkpoint abrogation, which leads to 
inappropriate mitotic entry. Further, subsequent to delays in late S and G2 phases following   
X-irradiation, G2/M checkpoint abrogation was observed which was correlated with four to sixfold 
increase in cyclin B1 content per cell [101]. Previous reports of moderate hyperthermic studies of 
mitotic catastrophe and decreases in clonogenic survival have implicated with lethality. For example, a 
12h exposure of S-phase CHO cells to 41.5 °C hyperthermia lead to a 50% incidence of mitotic 
catastrophe and a corresponding decrease in survival [102] and chronic exposure of HeLa cells to  
41.5 °C produced a yield of spontaneous premature chromosome condensation (SPCC) followed by 
nuclear fragmentation, which showed a one-to-one correlation with cell killing [103]. Therefore, 4h, 
41.5 °C (non-lethal) exposure delivered prior to X-irradiation produced maximal radiosenstization 
[104], yet no studies have demonstrated a causal role for SPCC in lethality under moderate 
hyperthermia. 
An optimization treatment planning model was designed that specifies the most appropriate laser 
parameters to permit complete tumor destruction by maximizing injury and eliminating HSP 
expression in the tumor. The model also permits preservation of the healthy surrounding tissue by 
minimizing the tissue injury and enhancing recovery by induction of HSP expression at 43.8 °C in the 
tumor region and 42.8 °C in the healthy tissue [105,106]. Extended heating durations of 30 minutes are 
required to induce sufficient thermal injury for these therapies. The equivalent thermal dose of 48.8 °C 
for 1 min enabled comparison with the HSP and injury fraction based optimization. The temperature-
based optimization yielded an insufficient amount of thermal injury and high levels of HSP expression 
in the tumor. Without imposing more stringent constraints and objective functions based on desired 
thermal injury fraction and HSP expression, the lack of thermal injury and elevated HSP expression in 
the tumor is certain to result in tumor recurrence and resistance to subsequent chemotherapy and 
radiation treatments. Cancers 2011, 3                               
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Implementation of both HSP expression and injury fraction objective functions based on cellular 
and tissue data in the optimization process permitted successful selection of truly optimal therapies 
with maximum injury and elimination of HSP expression in the tumor and minimum injury and HSP 
expression elevation in the healthy tissue. The temperature prediction provided by the Penne’s 
equation corresponds closely with measured data using Magnetic Resonance Thermometry during 
laser irradiation of prostate tumors [105,106]. The steepest descent method for optimization was 
capable of determining effective laser parameters based on specified objective functions developed 
from strict criteria related to the desired tissue response. Alternate optimization strategies such as 
Newton’s or quasi-Newton’s method could deliver a better convergence rate, however, its utilization 
will provide minimal improvement due to the existing efficiency of the adaptive finite element 
algorithm which reaches convergence within very few steps and requires minimal CPU time. 
Incorporating appropriate thermal and optical properties for the tissue of interest for the temperatures 
and wavelengths considered is critical to achieving accurate prediction and optimization of the tissue 
response to laser therapy. Currently, the model does not incorporate the dynamic optical properties 
associated with denaturation of proteins during the laser heating process, which may lead to alterations 
in tissue absorption and scattering properties.  
6.4. Strategies to Overcome Radiation-Induced Damage 
Modern targeted radiotherapy aims to cause maximum killing of cancer cells while minimizing 
damage to normal tissue. However, these treatments are not without side effects, and cancer survivors 
are still at an increased risk of developing a range of unpleasant, and even life-threatening, side effects. 
These side effects are caused by a combination of normal cell killing (both parenchymal and vascular 
cells) and stimulation of inflammatory, thrombotic and fibrogenic processes. Side effects may develop 
during or shortly after a course of fractionated radiotherapy (e.g., mouth ulcers or dry mouth after 
radiotherapy for head and neck cancer) or many months to years after the end of treatment (e.g., frozen 
shoulder edema and fibrosis or heart failure after radiotherapy for breast cancer, or cognitive defects 
after irradiation of brain metastases). Modifiers of normal tissue responses to ionizing radiation can be 
classified as prophylactic (radioprotectors), mitigators or therapeutic agents. Prophylactic agents, given 
before ionizing radiation exposure, include free radical scavengers that prevent the fixation of the 
initial radiochemical event, inhibitors of p53-induced early apoptotic cell death and antioxidants that 
inhibit early inflammatory reactions. Mitigators are given during or shortly after radiotherapy, before 
clinical presentation of ionizing radiation injury. They include antioxidants, growth factors and stem 
cell- or progenitor cell-based approaches to stimulate proliferative regeneration and support the 
survival and differentiation of healthy normal cells. Strategies for reducing the severity of acute 
ionizing radiation reactions aim to either prevent initial cell death or stimulate the regeneration of 
damaged tissues. Radical scavengers are effective when given before irradiation and, as they react with 
free radicals in competition with oxygen, the degree of radioprotection is highly dependent on oxygen 
tension, being maximal at intermediate oxygenation [107]. Amifostine has emerged as the best radical 
scavenging radioprotector in terms of efficacy to toxicity ratio and it has been widely tested in the 
clinic, particularly for reducing the incidence of xerostomia in patients with head and neck cancer. Cancers 2011, 3                               
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Protection against ionizing radiation-induced pneumonitis has also been reported in some clinical trials 
in patients with lung cancer [108]. 
Haematopoietic growth factors have been used for many years to stimulate the recovery of the bone 
marrow and to prevent chemotherapy or total body irradiation (TBI)-induced neutropenia after 
myeloablative conditioning for stem cell transplantation. This approach is now being extended to  
non-haematopoietic growth factors, such as keratinocyte growth factor (KGF), and preclinical studies 
have shown substantial protection against ionizing radiation-induced oral mucositis [109], intestinal 
damage [110] and pneumonitis [111]. Transient inhibition of p53 can be an effective strategy for 
protection against acute ionizing radiation injury in specific epithelial and lymphoid tissues, through 
the direct inhibition of apoptosis in the relevant stem cell compartments. p53 has an essential role in 
mediating cell cycle arrest and apoptosis in response to gentoxic insults, thus preventing the replication 
of cells with damaged DNA and inhibiting tumorigenesis. However, p53-dependent apoptosis of stem 
cells also results in acute ionizing radiation injury in several normal tissues including the bone marrow, 
intestine and testes. Transient inhibition of p53 (by genetic manipulation or small-molecule inhibitors) 
has been shown to provide effective protection against bone marrow and intestinal apoptosis after TBI 
of mice, without promoting tumor formation or influencing the ionizing radiation sensitivity of tumors 
[112]. Mesenchymal stem cells (MSC) have extensive proliferative capacity and they can be selected 
from the bone marrow (on the basis of specific cell surface markers) and expanded in vitro before 
transplantation. Systemically delivered MSC have been shown to engraft in irradiated skin, esophagus 
and intestine and to stimulate tissue regeneration and to reduce the severity of ionizing radiation 
damage [113]. Although stem cells have now been isolated and expanded from several normal tissues, 
the salivary gland is, so far, the only tissue in which transplanted adult stem cells have been shown to 
both localize to the irradiated tissue and to lead to an improvement of tissue structure and function 
[114]. One earlier study found that transplantation of immortalized embryonic neural stem cells 
delayed the onset of ionizing radiation-induced paralysis after cervical cord irradiation [115]. 
Vascular damage is one of the major underlying causes of late ionizing radiation injury. In small 
vessels endothelial cell damage initiates inflammatory and coagulation cascades, which lead to 
vascular leakage, micro-thrombus formation and secondary tissue ischemia. Overproduction of   
inflammatory cytokines, such as TGF-β and thrombin, also drives smooth muscle cell proliferation and 
collagen production in fibroblasts, initiating the development of fibrosis. Restoration of the thrombo–
hemorrhagic balance in endothelial cells [116] and the inhibition of ionizing radiation-induced 
activation of TGF-β  [117]. Animal studies have shown that bone marrow-derived dendritic cells 
(BMDC) efficiently engraft to ionizing radiation-damaged tissue and contribute to tissue repair and 
improve the function of the esophagus [113] and salivary gland [118]. Only very limited incorporation 
and clonal expansion of mobilized or transplanted cells into the irradiated gland was seen, although 
newly formed blood vessels did contain bone marrow-derived dendritic cells. Because of the paracrine 
effects, such as secreted growth factors and cytokines, stimulated vascular regeneration and the 
proliferation of surviving stem cells thus contributed to reduced damage [118]. 
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7. Current and Future Radiation Oncology Strategies  
One further direction to reduce dosage to the heart in selected indications might also be 
radiotherapy with particles such as carbon or helium ions and protons. Charged particles have different 
depth dose distributions as opposed to photons, depositing most of their energy at the very end of their 
trajectory in tissue, which results in a very sharp and localized peak of dose (Bragg peak). Compared 
to advanced photon techniques, radiotherapy with particles therefore offers potential, especially where 
(large) geometrically complex target volumes are located in close proximity to organs at risk and 
necessitating steep dose fall-off. One example of cardiac sparing by means of proton radiotherapy in 
dosimetric studies is treatment of the breast including regional nodes [119]. For centrally or superiorly 
located stage I non-small cell lung cancer (NSCLC), proton therapy, in particular intensity-modulated 
proton therapy (IMPT), can deliver ablative doses to the target volume and significantly reduce doses 
to normal tissues (heart, aorta, pulmonary vessels, lung, brachial plexus, spinal cord) compared with 
photon stereotactic body radiation therapy [120]. Compared with intensity modulated photon 
radiotherapy, IMPT spared more lung, heart, spinal cord, and esophagus, even with a dose escalation 
from 63 Gy to 83.5 Gy [121]. 
The prevalence of cardiac complications will realistically decrease in patients treated recently. 
Radiation-induced late complications in organs at risk can obviously be reduced rather than avoided by 
diminishing radiation dose to these organs. To this end, continuous efforts are aimed at minimizing the 
dose delivered to organs at risk while maintaining or even maximizing the dose to the target. Recent 
but widely implemented techniques contributing greatly to conformal dose distribution, particularly in 
the thorax, include image guidance (IGRT), e.g., using kV imaging and cone beam computed 
tomography to reduce set-up errors and intensity-modulated photon radiotherapy (IMRT) [122]. IMRT 
can improve conformality compared with conformal 3D techniques, especially in cases of 
geometrically complex targets. However, multifield IMRT produces a bath of low doses to greater 
volumes of normal tissues. Consequently, concern exists about the appraisal of IMRT in terms of 
avoiding cardiac complications.  
8. Conclusions 
Hyperthermia treatment has shown promising results in the treatment of cancer patients. Heat does 
not induce DNA double-strand breaks but rather appears to inhibit repair of DNA damage especially in 
the case of IR-induced DNA damage, which produces complex closely clustered damage on opposed 
DNA strands, heat shock pre-irradiation results in delays in completing multi-step repair processes. 
Heat may also cause protein aggregates to sequester the proteins involved in DNA damage repair. Heat 
shock proteins modulate the effects of heat by binding unfolded protein domains and maintaining the 
protein in a soluble form until it can be refolded or degraded, thereby minimizing protein aggregation. 
Moreover, HSP have been shown to enhance the function of DNA repair enzymes such as human 
apurinic/apyrimidinic endonuclease. Clinical studies have shown that hyperthermia can directly kill 
tumor cells and can act as a sensitizer for radiation therapy or chemotherapy. Hyperthermia is a potent 
radiosensitizer that has been under clinical investigation as a means to improve the response to   
IR–based cancer treatments that acts to improve the local tumor control. Hyperthermia itself has Cancers 2011, 3                               
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several cellular effects that should be synergistic with IR-induced tumor cell killing. Unlike the IR 
response, neither hypoxic nor plateau-phase cells are resistant to heat-induced cell killing. Clinical 
trials have shown significant benefits from adding hyperthermia to radiotherapy regimens for a number 
of malignancies and understanding the mechanisms involved in heat-mediated IR sensitization has 
become clinically important. Therefore, targeting a combination of tumor specific and DNA repair 
pathways will not only enhance heat-induced radiosensitization, but will also decrease the overall level 
of normal tissue toxicity occurring during radiotherapy, which could eventually help to improve 
sequencing of the heat and IR treatment to obtain a better clinical outcome. The combination of 
specificity and efficacy of an approach can be considered as a measure of its merit. Attacking or 
exploiting hypoxia is highly tumor specific, because hypoxia occurs almost universally in solid tumors 
and is rare in normal tissues. Increasing cellular radiosensitivity is not tumor specific, because DNA 
repair and signal transduction pathways that influence radiosensitivity also operate, and are often 
essential, for normal tissue survival and function. Modulating cell cycle checkpoints can be regarded 
as another approach for increasing tumor cell radiosensitivity that is partially tumor specific because, 
as discussed above, most tumors have a defective G1/S checkpoint, rendering them more susceptible 
than normal tissues to the inhibition of the remaining checkpoints. Approaches to protect normal 
tissues by reducing sensitivity to ionizing radiation may be risky unless there is good specificity for 
non-malignant cells. It will be very interesting to give hyperthermia and irradiation simultaneously, but 
there is no equipment available to date. 
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